US › Healthcare

Anavex Life Sciences Corp (AVXL)

US · Healthcare · Biotechnology

$2.41+2.12%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-3.2M

EPS

$0.08

EPS estimate

$-0.08

EPS came in at 0.08 against a street estimate of -0.08 — a beat of 200.0%.

Key statistics

Market cap

$218.8M

Forward P/E

3.9

P/B

2.01

Book value

$1.21

EPS (TTM)

$-0.14

52-week high

$10.38

52-week low

$2.25

50-day MA

$2.86

200-day MA

$3.47

Beta

1.14

Analyst view

Analysts rate Anavex Life Sciences Corp a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $20.00.

Shareholding

Insiders

1.71%

Institutions

40.70%

Largest institutional holders

Fund	Stake
BlackRock Inc	8.21%
State Street Corp	4.87%
Vanguard Capital Management, LLC	4.17%
Two Sigma Investments LLC	3.29%
Geode Capital Management, LLC	2.36%
Federated Hermes Inc	1.16%
Susquehanna International Group, LLP	1.07%
Summit Financial LLC	0.98%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Anavex Life Sciences Corp — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.